You get the GIST.

What’s the knee-jerk answer to every tumor board question on advanced gastrointestinal stromal tumor (GIST)? Imatinib, aka Gleevec. But it rarely works forever. Dasatinib is a clever tyrosine kinase inhibitor (TKI) of multiple targets including certain KIT and PDGFRA domains that become resistant to imatinib. A multi-institutional single arm study evaluated dasatinib 70 mg twice daily in 48 patients with imatinib-refractory GIST. The rate of progression-free survival at 6 months was 29%, just shy of their goal of 30%. Unimpressed? So were the authors who stopped enrolling in 2009 and just got around to reporting 6-month outcomes. | Schuetze, JAMA Oncol 2018